Skip to content

Author

Yaxiong Zhang

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Integration of a severe immune-related adverse events predictive model with efficacy biomarkers enables precise stratification in NSCLC immunotherapy: insights from the phase 3 ORIENT-11 study

Severe immune-related adverse events (irAEs) compromise the outcomes of immune checkpoint inhibitors (ICIs). However, in routine practice, clinicians still lack biomarkers that can prospectively disentangle antitumor efficacy from the risk of severe irAEs, resulting in largely empirical, one-size-fits-all use of...

Yuecheng Peng, Ling Wen, Jia-Le Shen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.